MX9800239A - Metodos para el tratamiento y prevencion de diabetes. - Google Patents

Metodos para el tratamiento y prevencion de diabetes.

Info

Publication number
MX9800239A
MX9800239A MX9800239A MX9800239A MX9800239A MX 9800239 A MX9800239 A MX 9800239A MX 9800239 A MX9800239 A MX 9800239A MX 9800239 A MX9800239 A MX 9800239A MX 9800239 A MX9800239 A MX 9800239A
Authority
MX
Mexico
Prior art keywords
diabetes
prevention
treatment
methods
peptides
Prior art date
Application number
MX9800239A
Other languages
English (en)
Inventor
Marco Londei
G Leslie R David
Paul J Conlon
Nicholas Ling
Amitabh Gaur
Original Assignee
Neurocrine Biosciences Inc Ken
Inst Of Rheumatology
St Bartholomew S Hospital Ct
For Clinical Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc Ken, Inst Of Rheumatology, St Bartholomew S Hospital Ct, For Clinical Res filed Critical Neurocrine Biosciences Inc Ken
Publication of MX9800239A publication Critical patent/MX9800239A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Los péptidos y análogos de péptidos de la isoforma de 65KD de descarboxilasa de ácido glutámico, para utilizarse en el tratamiento y prevencion de diabetes. Los análogos de péptidos contienen generalmente de uno a tres alteraciones de aminoácidos. Los péptidos y análogos pueden utilizarse para diagnosticar diabetes y detectar una predisposicion a diabetes.
MX9800239A 1995-06-23 1998-01-07 Metodos para el tratamiento y prevencion de diabetes. MX9800239A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/494,624 US5945401A (en) 1995-06-23 1995-06-23 Peptide analogues of the 65KD isoform of human glutamic acid decarboxylase and uses thereof

Publications (1)

Publication Number Publication Date
MX9800239A true MX9800239A (es) 1998-11-29

Family

ID=23965258

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9800239A MX9800239A (es) 1995-06-23 1998-01-07 Metodos para el tratamiento y prevencion de diabetes.

Country Status (7)

Country Link
US (1) US5945401A (es)
EP (1) EP0871657A1 (es)
JP (1) JPH11514847A (es)
AU (1) AU6478696A (es)
CA (1) CA2225406A1 (es)
MX (1) MX9800239A (es)
WO (1) WO1997000891A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003273679A1 (en) * 2002-06-11 2003-12-22 Merck Patent Gmbh Method for mapping and eliminating t-cell epitopes
NZ539106A (en) 2002-10-10 2007-02-23 Yeda Res & Dev Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents
NZ560359A (en) * 2005-02-04 2009-11-27 Dow Agrosciences Llc Anti-T cell and autoantigen treatment of autoimmune disease using CD3 monoclonal antibodies and glutamic acid decarboxylase, insulin, beta cell protein or a combination thereof.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041380A (en) * 1982-08-04 1991-08-20 La Jolla Cancer Research Foundation Tetrapeptide
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
US5547847A (en) * 1993-09-07 1996-08-20 University Of Washington Diagnosis of insulin-dependent diabetes

Also Published As

Publication number Publication date
US5945401A (en) 1999-08-31
JPH11514847A (ja) 1999-12-21
CA2225406A1 (en) 1997-01-09
AU6478696A (en) 1997-01-22
WO1997000891A1 (en) 1997-01-09
EP0871657A1 (en) 1998-10-21

Similar Documents

Publication Publication Date Title
DE69431060D1 (de) Klonierte glutaminsäure-decarboxylase
DE3272220D1 (en) Physiologically active peptide with between 147 and 162 amino acid residues
NZ315809A (en) Opiate tetrapeptides with a tyr (or 2',6'-dimethyl tyr) at one terminus and an optionally substituted amino at the other terminus
IL124536A0 (en) A glycine uptake antagonist
DE69731373D1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
ES2160485A1 (es) Peptidos inhibidores de la exorcitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.
PL312989A1 (en) Therapeutic derivatives of peptides
SE8703938D0 (sv) Peptide derivatives
HUP9800727A3 (en) Thrombin inhibitors based on the amino acid sequence of hirudin
CA2153789A1 (en) Biologically active tgf-.beta.1 and tgf-.beta.2 peptides
TW364850B (en) Nematocidal compositions
ZA9810679B (en) Antimicrobial peptides.
PL321091A1 (en) Analogues of peptide p@&& and pharmaceutic sets of components containing them, used in treatment or diagnosis of diabetes
EP0366638A3 (en) Neuromodulatory peptide
MX9703642A (es) Metodos para el tratamiento de esclerosis multiple utilizando analogos de peptido en la posicion 91 de la proteina basica de mielina humana.
UA32523C2 (uk) Пептиди, які мають високу біологічну активність, та фармацевтична композиція на їх основі
WO1996028470A3 (en) Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
MY124560A (en) Amino acid compositions and use thereof in immunosuppression
MY106287A (en) Acid addition salts of amidated taurine or glycine, their preparation and use
CA2186423A1 (en) Protein which induces interferon-gamma production by immunocompetent cell
GR852541B (es)
HU9503593D0 (en) Factor vii-derived peptides
MX167236B (es) Peptidos sinteticos de timosina -1 y metodo para su obtencion
MX9800239A (es) Metodos para el tratamiento y prevencion de diabetes.
IL111196A0 (en) Peptides and pharmaceutical compositions comprising them